| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/08/2009 | CA2213466C Inhibitors of microsomal triglyceride transfer protein and method |
| 09/03/2009 | WO2009108657A2 Heteroaryl derivatives as cftr modulators |
| 09/03/2009 | WO2009108332A1 INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
| 09/03/2009 | WO2009108153A1 Methods and compositions for the regulation of lectin complement pathway (lcp)- associated complement activation in hyperglycemic myocardial damage |
| 09/03/2009 | WO2009107660A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 09/03/2009 | WO2009107398A1 High-molecular-weight adiponectin measurement method |
| 09/03/2009 | WO2009107389A1 Tricyclic compound |
| 09/03/2009 | WO2009107387A1 2-oxochromene derivative |
| 09/03/2009 | WO2009106708A2 Azetidine derivatives, their preparation and their application in therapy |
| 09/03/2009 | WO2009106565A1 Agonists of gpr119 |
| 09/03/2009 | WO2009106561A1 Pyrazine compounds for treating gpr119 related disorders |
| 09/03/2009 | WO2009106559A1 Uses of indane compounds |
| 09/03/2009 | WO2009106203A1 Glucokinase activators |
| 09/03/2009 | WO2009105823A1 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| 09/03/2009 | WO2009085198A3 Combination of metformin r-(+)-lipoate and antiobesity agents for the treatment of diabetic hyperglycemia and diabetic complications |
| 09/03/2009 | WO2009053487A3 Proteins that stimulate the secretion of satiety hormones |
| 09/03/2009 | WO2009049742A3 Use of melanotrophin-potentiating factor as a therapeutic agent |
| 09/03/2009 | WO2009046829A3 Casoxin d as a therapeutic agent |
| 09/03/2009 | WO2009043480A3 Use of leptin (22-56 ) as a therapeutic agent |
| 09/03/2009 | WO2009043469A3 Use of pneumadin as a therapeutic agent |
| 09/03/2009 | WO2009040018A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009040017A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009039993A3 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 09/03/2009 | WO2009039992A3 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 09/03/2009 | WO2009039988A3 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 09/03/2009 | WO2009033805A3 Use of somatostatin-14 as a therapeutic agent |
| 09/03/2009 | WO2009033802A3 Antide as a therapeutic agent |
| 09/03/2009 | WO2009033801A3 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 09/03/2009 | WO2009033755A3 Use of l-carnosine as a therapeutic agent |
| 09/03/2009 | WO2009033741A3 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) |
| 09/03/2009 | WO2009033737A3 Use of gluten exorphin c : as a therapeutic agent |
| 09/03/2009 | WO2009033731A3 Use of a laminin peptide as a therapeutic agent |
| 09/03/2009 | WO2009033723A3 Use of aip2 as a therapeutic agent |
| 09/03/2009 | WO2009033714A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009033692A3 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents |
| 09/03/2009 | WO2009033665A3 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent |
| 09/03/2009 | WO2009033656A3 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection |
| 09/03/2009 | US20090222955 Delta 6 desaturases from primulaceae, expressing plants and pufa-containing oils |
| 09/03/2009 | US20090221821 Adenosine receptor antagonists and methods of making and using the same |
| 09/03/2009 | US20090221712 Mandelic hydrazides |
| 09/03/2009 | US20090221710 Acyclic Sulfamide Derivatives |
| 09/03/2009 | US20090221705 Omega 3 |
| 09/03/2009 | US20090221694 Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone |
| 09/03/2009 | US20090221686 Modulation of the Transcription of Pro-Inflammatory Gene Products |
| 09/03/2009 | US20090221677 Methods for Reducing Body Fat and Increasing Lean Body Mass by Reducing Stearoyl-COA Desaturase 1 Activity |
| 09/03/2009 | US20090221671 Modulation of lmw-ptpase expression |
| 09/03/2009 | US20090221660 Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471 |
| 09/03/2009 | US20090221652 Combinations of metformin and meglitinide |
| 09/03/2009 | US20090221645 Dihydroimidazothiazole Derivatives |
| 09/03/2009 | US20090221644 Gpcr Agonists |
| 09/03/2009 | US20090221639 Heterocyclic GPCR Agonists |
| 09/03/2009 | US20090221602 Processes for preparing substituted pyrimidines |
| 09/03/2009 | US20090221595 Crystalline form of sitagliptin |
| 09/03/2009 | US20090221592 New salt of sitagliptin; exhibits physicochemical properties, such as stability to stress, rendering it particularly suitable for the manufacture of various pharmaceutical dosage forms; Type 2 diabetes |
| 09/03/2009 | US20090221591 Selective Inhibitors of Human Corticosteroid Synthases |
| 09/03/2009 | US20090221584 Bisaryl-sulfonamides |
| 09/03/2009 | US20090221583 such as 4-Benzenesulfinyl-N-{2-oxo-2-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethyl}-benzamide, used for the treatment of syndrome X, obesity, insulin resistance, dyslipidemia and cardiovascular diseases |
| 09/03/2009 | US20090221546 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 09/03/2009 | US20090221526 NGNA Compositions and Methods of Use |
| 09/03/2009 | US20090221511 Trpv1 + sensory neurons control of beta-cell stress and islet inflammation in diabetes |
| 09/03/2009 | US20090220586 Proteomimetic compounds as inhibitors of the interaction of nuclear receptor with coactivator peptides |
| 09/03/2009 | US20090220518 Methods and compositions for treatment of graft rejection and promotion of graft survival |
| 09/03/2009 | US20090220505 Methods of inhibiting amyloid toxicity |
| 09/03/2009 | US20090220452 Method Of Producing A Modified (POLY) Peptide |
| 09/03/2009 | DE19521720B4 Insulinanalogonformulierungen Insulin analog formulations |
| 09/03/2009 | CA2716852A1 High-molecular-weight adiponectin measurement method |
| 09/03/2009 | CA2716780A1 Prophylactic or therapeutic agent for diabetes or obesity |
| 09/03/2009 | CA2716599A1 Glucokinase activators |
| 09/03/2009 | CA2716250A1 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| 09/03/2009 | CA2716128A1 Inhibitors of 11.beta.-hydroxysteroid dehydrogenase type 1 |
| 09/03/2009 | CA2716109A1 Heteroaryl derivatives as cftr modulators |
| 09/03/2009 | CA2714351A1 Novel compositions containing xanthohumol-cyclodextrin complexes |
| 09/03/2009 | CA2709863A1 Azetidine derivatives, their preparation and their application in therapy |
| 09/02/2009 | EP2096120A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 09/02/2009 | EP2096111A1 Pyrazoles and use thereof as drugs |
| 09/02/2009 | EP2096109A1 Carboxylic acid derivative |
| 09/02/2009 | EP2094706A2 Substituted 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands |
| 09/02/2009 | EP2094704A2 Cis-cyclohexyl substituted pyrimidinone derivatives |
| 09/02/2009 | EP2094695A1 Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| 09/02/2009 | EP2094683A2 Bicyclic compounds and use as antidiabetics |
| 09/02/2009 | EP2094666A1 Cannabinoid receptor modulators |
| 09/02/2009 | EP2094663A2 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| 09/02/2009 | EP2094643A2 N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| 09/02/2009 | EP2094640A1 Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar). |
| 09/02/2009 | EP2094306A2 Treatment of il-1-beta related diseases |
| 09/02/2009 | EP2094303A1 Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof |
| 09/02/2009 | EP2094302A2 Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| 09/02/2009 | EP2094262A1 Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094261A1 Pharmaceutical composition containing naphthoquinone-based compound for intestine delivery system |
| 09/02/2009 | EP2094254A1 Treatment of cachexia |
| 09/02/2009 | EP2024338B1 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments |
| 09/02/2009 | EP1937672B1 N-[(4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use |
| 09/02/2009 | EP1641763B1 4-cyanopyrazole-3-carboxamide derivatives preparation and therapeutic application thereof |
| 09/02/2009 | EP1523372B1 Ghrelin-carrier conjugates |
| 09/02/2009 | EP1478233A4 Method for administering glp-1 molecules |
| 09/02/2009 | EP1470137B1 Edg receptor agonists |
| 09/02/2009 | EP1466925B1 Antibodies against fibroblast growth factor 23 |
| 09/02/2009 | EP1458392B1 Acridones as inhibitors of impdh enzyme |
| 09/02/2009 | EP1353663B1 Fenofibrate tablets |
| 09/02/2009 | EP1317479B1 Methods and compositions for diseases associated with amyloidosis |